Literature DB >> 31874360

Anti-N-methyl-D-aspartate receptor encephalitis with accompanying ovarian teratoma in female patients from East China: Clinical features, treatment, and prognostic outcomes.

Lu Zhang1, Yao Lu1, Lan Xu1, Lu Liu2, Xunyi Wu3, Youzhong Zhang4, Guoxing Zhu1, Zhen Hong1.   

Abstract

PURPOSE: The association between anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis) and teratoma is formally recognized. This study compared the clinical features, treatments and outcomes between female patients with or without accompanying teratomas and determined the potential influences of coexisting teratomas.
METHOD: Fifty-six female patients diagnosed with anti-NMDAR encephalitis were enrolled in two major tertiary hospitals in East China from January 2013 through March 2018 and were grouped as patients with or without teratoma. The clinical features were reviewed, and follow-up studies were performed. Comparisons were made between the two groups.
RESULTS: Patients with teratoma reported fewer viral prodromes (p = 0.0085) and stronger positive intensity of anti-NMDAR antibodies in cerebrospinal fluid (CSF) (p = 0.0368), while nontumor patients tended to demonstrate lymphocytic pleocytosis in CSF (p = 0.0306). Seizure types varied between individuals, with complex partial seizures more common in teratoma patients (p = 0.0105). Nontumor patients frequently required combinations of first-line and second-line immunotherapy (p = 0.0014), which may be attributed to higher mRS scores at admission (p = 0.0300). Also, they had higher mean mRS scores since the 12-month follow-up and greater probability of relapse than did patients with teratomas (p = 0.0286).
CONCLUSIONS: Symptomatology and auxiliary findings indicate that ovarian teratoma may be the immunologic trigger for anti-NMDAR encephalitis patients, while viral infection is likely to play a major part in pathogenesis for those without any detectable tumor. Overall, anti-NMDAR encephalitis patients with teratomas present with milder neurological symptoms and have better long-term outcomes after tumor removal.
Copyright © 2019 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-NMDAR encephalitis; Lymphocytic pleocytosis; Ovarian teratoma; Viral prodrome

Mesh:

Year:  2019        PMID: 31874360     DOI: 10.1016/j.seizure.2019.12.016

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  6 in total

Review 1.  Ovarian Teratoma-Related Paraneoplastic Neurological Syndromes.

Authors:  Jingfang Lin; Minjin Wang; Jierui Wang; Jinmei Li
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

2.  Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis: A Cohort Study in Western China.

Authors:  Xue Gong; Chu Chen; Xu Liu; Jingfang Lin; Aiqing Li; Kundian Guo; Dong Zhou; Zhen Hong
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-02-15

Review 3.  The Association of Ovarian Teratoma and Anti-N-Methyl-D-Aspartate Receptor Encephalitis: An Updated Integrative Review.

Authors:  Cheng-Yang Wu; Jiann-Der Wu; Chien-Chin Chen
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923

4.  Long-Term Prognosis of Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis Who Underwent Teratoma Removal: An Observational Study.

Authors:  Hesheng Zhang; Weixi Xiong; Xu Liu; Wenyu Liu; Dong Zhou; Xintong Wu
Journal:  Front Neurol       Date:  2022-04-12       Impact factor: 4.003

5.  Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.

Authors:  Kundian Guo; Xu Liu; Jingfang Lin; Xue Gong; Aiqing Li; Yue Liu; Dong Zhou; Zhen Hong
Journal:  Ther Adv Neurol Disord       Date:  2022-01-19       Impact factor: 6.570

6.  Anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma in Korea: three case reports.

Authors:  Jisun Lee; Seongwoo Kang; Hye Jin Chang; Yong Hee Lee; Joo-Hyuk Son; Tae Wook Kong; Suk-Joon Chang; Kyung Joo Hwang; Miran Kim
Journal:  Yeungnam Univ J Med       Date:  2021-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.